AI assistant
Axogen, Inc. — Director's Dealing 2018
Dec 31, 2018
32414_dirs_2018-12-31_46617af8-b57a-4deb-a3fa-f3c479ad9ac9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AxoGen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2018-12-27
Reporting Person: Scopelianos Angelo (VP Research & Development)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-12-27 | Employee Stock Option (right to purchase) | $19.17 | A | 32900 | Acquired | 2028-12-27 | Common Stock (32900) | Direct |
| 2018-12-27 | Restricted Stock Units | $ | A | 4600 | Acquired | Common Stock (4600) | Direct |
Footnotes
F1: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.
F3: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.